Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EXPERIENCE WITH MORICIZINE HCL IN CHILDREN WITH SUPRAVENTRICULAR TACHYCARDIA
Autore:
MEHTA AV; SUBRAHMANYAM AB; LONG JB; KANTER RJ;
Indirizzi:
E TENNESSEE STATE UNIV,DEPT PEDIAT,DIV PEDIAT CARDIOL,JAMES H QUILLENCOLL MED JOHNSON CITY TN 37614 DUKE UNIV,MED CTR DURHAM NC 27710
Titolo Testata:
International journal of cardiology
fascicolo: 1, volume: 57, anno: 1996,
pagine: 31 - 35
SICI:
0167-5273(1996)57:1<31:EWMHIC>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
JUNCTIONAL ECTOPIC TACHYCARDIA; EFFICACY; ETHMOZIN; DRUG; ARRHYTHMIAS;
Keywords:
SUPRAVENTRICULAR TACHYCARDIA IN CHILDREN; MORICIZINE; JUNCTIONAL ECTOPIC TACHYCARDIA; ATRIAL ECTOPIC TACHYCARDIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
15
Recensione:
Indirizzi per estratti:
Citazione:
A.V. Mehta et al., "EXPERIENCE WITH MORICIZINE HCL IN CHILDREN WITH SUPRAVENTRICULAR TACHYCARDIA", International journal of cardiology, 57(1), 1996, pp. 31-35

Abstract

Eight children, age between 4.5 and 19 years were treated with moricizine for supraventricular tachycardia during the last 3 years. The tachycardia was documented by surface electrocardiogram (EGG), and/or by ambulatory ECG in all the children and the mechanism of tachycardia was determined by previously published surface ECG and electrophysiologic criteria in all but one child. Of the eight children, three had atrial ectopic tachycardia, three had automatic junctional ectopic tachycardia, one had atrioventricular (AV) nodal reentry tachycardia and one had atrial reentry. All the children except one had failed trial of two or more antiarrhythmic drugs prior to moricizine therapy. The duration of moricizine therapy ranged from 4 days to 25 months. In three of the eight children (patients 3, 5 and 7), who presented with AV nodal reentrant tachycardia, automatic junctional ectopic tachycardia and atrial ectopic tachycardia, respectively, moricizine therapy was effective in restoring sinus rhythm and controlling the clinical tachycardia. Only one child (patient 1) developed proarrhythmia, an episode of fast, narrow-QRS supraventricular tachycardia lasting for 30 s, on the third day of therapy. This was subsequently confirmed by electrophysiologic study to be AV nodal reentrant tachycardia. The other side effectsnoted were non-cardiac, not dose-dependant and did not require dis-continuation of therapy. Based on our small series and those of others, moricizine, a newer class I anti-arrhythmic agent, has a limited but useful role in the management of recalcitrant type of supraventricular tachycardia, such as ectopic atrial and junctional tachycardia in children.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 03:34:27